600521 华海药业
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入6,408,882-11.57%9,547,4258,308,7208,265,7456,643,573
减:营业总成本5,972,3200.53%7,978,7397,096,9006,635,6946,300,680
    其中:营业成本2,454,251-9.30%3,636,6043,288,3383,110,9362,657,134
               财务费用167,82338.06%95,480137,247(10,833)188,184
               资产减值损失(70,395)102.99%(122,874)(117,176)(70,604)(13,928)
公允价值变动收益59,175-214.25%(69,493)(100,248)5,201299,808
投资收益17,343-177.46%(28,720)(62,652)(75,205)147,151
    其中:对联营企业和合营企业的投资收益(18,117)-20.50%(28,660)(27,700)(42,191)(41,774)
营业利润555,158-57.85%1,470,7891,124,5401,547,171868,399
利润总额549,157-58.12%1,463,6081,100,3211,508,900786,928
减:所得税费用175,227-36.05%356,145283,072332,890306,284
净利润373,930-63.95%1,107,463817,2491,176,009480,644
减:非控股权益(6,426)-207.47%(11,518)(13,217)8,251(6,891)
股东净利润380,356-63.12%1,118,981830,4661,167,759487,535

市场价值指针
每股收益 (元) *0.260-63.38%0.7700.5700.8100.340
每股派息 (元) *----0.2500.2000.2400.100
每股净资产 (元) *6.1916.18%5.9035.2864.925--
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容